Linda M. Richardson - Jan 27, 2022 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC. (ICPT)

Role: EVP & Chief Commercial Officer
Signature: /s/ Rocco Venezia, as attorney-in-fact
Stock symbol: ICPT
Transactions as of: Jan 27, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/31/2022, 03:15 PM
Previous filing: Jan 4, 2022
Next filing: Feb 15, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICPT	Common Stock	Award	$0	+10.3K	+42.35%	$0.00	34.6K	Jan 27, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ICPT	Option to Purchase Common Stock	Award	$0	+17.6K		$0.00	17.6K	Jan 27, 2022	Common Stock	17.6K	$14.44	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022.
F2	The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022.

Content

Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022.

The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022.